SG/CALL/ABBVIE/190/0.1/20.12.24 Share Price

DE000SU6FCC1

Market Closed - Boerse Frankfurt Warrants 01:19:17 15/06/2024 am IST
0.37 ^EUR	+19.35%

Current month	+89.47%
1 month	+44.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	15/06	MT
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer	15/06	PR
AbbVie inks immune disorder drug licensing deal with China's FutureGen	13/06	RE
AbbVie, FutureGen in License Pact for Inflammatory Bowel Disease Drug	13/06	DJ

More news

Quotes 5-day view

Date	Price	Change
14/24/14	0.36	+16.13%
13/24/13	0.31	+6.90%
12/24/12	0.29	-14.71%
11/24/11	0.34	-17.07%
10/24/10	0.41	+7.89%

Real-time Boerse Frankfurt Warrants

Last update June 15, 2024 at 01:19 am IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ABBVIE INC.
Issuer	Société Générale
WKN	SU6FCC
ISIN	DE000SU6FCC1
Date issued	29/12/2023
Strike	190 $
Maturity	20/12/2024 (188 Days)
Parity	10 : 1
Emission price	0.28 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	1.1 €
Lowest since issue	0.13 €
Spread	0.02 €
Spread %	5.26%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company